ArticleTranslational oncology2026

Multi-omics characterization identifies AHCY as a prognostic biomarker driving immunometabolic reprogramming in bladder cancer.

Qiao Peng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.